Magnetic Seizure Therapy for Psychotic Disorders
ConditionPsychotic Disorders
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-55
SponsorShanghai Jiao Tong University School of Medicine
About this trial
This trial aims to evaluate the efficacy and safety of Magnetic Seizure Therapy (MST) as an augmentation of antipsychotic medications for psychosis.
Eligibility criteria
Qualifiers
(1) meets the diagnostic criteria for schizophrenia or other primary psychotic disorders according to DSM-5;
(2) age range between 18 and 55 years;
(3) Positive And Negative Syndrome Scale (PANSS) score≥60;
(4) to provide informed consent.
Disqualifiers
(1) have a concomitant severe medical illness;
(2) are pregnant or intend to get pregnant during the study;
(3) have a history of DSM-5 diagnosis of substance dependence or abuse within the past three months;
(4) history of traumatic brain injury (with a screening scale score of 7 or above);
Trial design
Treatments tested in this trial
- Magnetic seizure therapy by Magnetic stimulator
- Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov